Last reviewed 2026-05-21 · How we verify

Tuselin (ALLOCLAMIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Tuselin (generic name: ALLOCLAMIDE) is a alloclamide drug. It is currently in Phase 2 development for Cough.

Tuselin works by interacting with the nervous system to reduce coughing.

Tuselin is a small molecule modality. It is also known as Alloclamide or Aloclamida.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ALLOCLAMIDE
Drug class	alloclamide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain is sending signals to your body to cough. Tuselin helps to block or reduce these signals, making it easier to breathe and reducing the urge to cough. This can provide relief for people with persistent or severe coughing.

Approved indications

Cough

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tuselin CI brief — competitive landscape report
Tuselin updates RSS · CI watch RSS

Frequently asked questions about Tuselin

What is Tuselin?

Tuselin (ALLOCLAMIDE) is a alloclamide drug, indicated for Cough.

How does Tuselin work?

Tuselin works by interacting with the nervous system to reduce coughing.

What is Tuselin used for?

Tuselin is indicated for Cough.

What is the generic name of Tuselin?

ALLOCLAMIDE is the generic (nonproprietary) name of Tuselin.

What drug class is Tuselin in?

Tuselin belongs to the alloclamide class. See all alloclamide drugs at /class/alloclamide.

What development phase is Tuselin in?

Tuselin is in Phase 2.

Drug class: All alloclamide drugs
Therapeutic area: All drugs in Other
Indication: Drugs for Cough

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing